Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw

Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks